Header image
 
 
 
 
 

 

Why vaccine

 

Despite considerable progress in the development of chemotherapeutic drugs like praziquantel, schistosomiasis still continues to be a disease of endemic proportion. However current research demonstrates that some individuals can acquire natural immunity to schistosome infection and successful animal models show encouraging prospect for vaccine development. In addition, the following rationales have been postulated by NR Bergquist for the need to develop schistosome vaccines. Since schistosomiasis don’t replicate in humans, a vaccine induced partial immunity is all that is required instead of sterile immunity; immune protection has been elucidated by using irradiated cercariae; vaccines are seen as the most cost-effective mechanism of infectious disease control; re-infection even after treatment with chemotherapy makes it hard to contain the disease in the long-term due to lack of infrastructure in developing world; expanded chemotherapy can potentially lead to drug resistance; development of vaccine allows us to integrate the short-term effect of the current drug therapy with the long-term employment of vaccines.